SCHEMBL6959807

SCHEMBL6959807

c1ccc2cc3c(N4CCNCC4)cccc3cc2c1

nearest known ligand 0.72

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HTR6 P50406 6/20 0.72
HTR5A P47898 3/20 0.72
HTR3E A5X5Y0 2/20 0.72
HTR3B O95264 2/20 0.72
HTR3A P46098 2/20 0.72
HTR3D Q70Z44 2/20 0.72
HTR3C Q8WXA8 2/20 0.72
SIGMAR1 Q99720 2/20 0.72
HTR2A P28223 2/20 0.72
HTR1A P08908 2/20 0.72
CYP1A2 P05177 1/20 0.72
CYP2D6 P10635 1/20 0.72
NCF1 P14598 1/20 0.72
TSHR P16473 1/20 0.72
NFKB1 P19838 1/20 0.72
HTR1D P28221 1/20 0.72
HTR1B P28222 1/20 0.72
HTR7 P34969 1/20 0.72
MTOR P42345 1/20 0.72
HSD17B10 Q99714 1/20 0.72

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4765408 0.90 HTR6 (0.58) HTR6HTR5AHTR3EHTR3BHTR3A
SCHEMBL27754466 0.87 HTR1A (0.52) HTR6HTR5AHTR3EHTR3BHTR3A
SCHEMBL3166780 0.84 HTR6 (1.00) HTR6HTR5AHTR3EHTR3BHTR3A
SCHEMBL29385724 0.84 HTR6 (1.00) HTR6HTR5AHTR3EHTR3BHTR3A
SCHEMBL240244 0.84 HTR6 (1.00) HTR6HTR5AHTR3EHTR3BHTR3A
SCHEMBL4723774 0.84 NCF1 (0.49) HTR6HTR5AHTR3EHTR3BHTR3A
SCHEMBL5366654 0.83 HTR6 (0.63) HTR6HTR5AHTR3EHTR3BHTR3A
Hydrochloric Acid SCHEMBL25379293 0.82 LMNA (1.00) HTR6HTR5AHTR3EHTR3BHTR3A
SCHEMBL4723171 0.82 KEAP1 (0.48) HTR6HTR5AHTR3EHTR3BHTR3A
Hydrochloric Acid SCHEMBL466870 0.82 LMNA (1.00) HTR6HTR5AHTR3EHTR3BHTR3A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 43 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12503458-B2 5-hydroxytryptamine receptor 7 activity modulators and their method of use TEMPLE UNIVERSITY OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) 2025-12-23 US disclosed
US-20240425487-A1 NOVEL 5-HYDROXYTRYPTAMINE RECEPTOR 7 ACTIVITY MODULATORS AND THEIR METHOD OF USE TEMPLE UNIVERSITY OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION 2024-12-26 US disclosed
US-11897870-B2 5-hydroxytryptamine receptor 7 activity modulators and their method of use Temple University-Of The Commonwealth System Higher Education (US) 2024-02-13 US disclosed
US-20220133713-A1 SIGMA-2 RECEPTOR BINDERS AND THEIR METHOD OF USE Temple University--of the Commonwealth System of Higher Education 2022-05-05 US disclosed
US-20220133713-A1 SIGMA-2 RECEPTOR BINDERS AND THEIR METHOD OF USE Temple University--of the Commonwealth System of Higher Education 2022-05-05 US disclosed
EP-3738955-A1 NOVEL 5-HYDROXYTRYPTAMINE RECEPTOR 7 ACTIVITY MODULATORS AND THEIR METHOD OF USE Temple University Of The Commonwealth System Of Higher Education (US) 2020-11-18 EP disclosed
EP-3738955-A1 NOVEL 5-HYDROXYTRYPTAMINE RECEPTOR 7 ACTIVITY MODULATORS AND THEIR METHOD OF USE Temple University Of The Commonwealth System Of Higher Education (US) 2020-11-18 EP disclosed
US-20200317648-A1 NOVEL 5-HYDROXYTRYPTAMINE RECEPTOR 7 ACTIVITY MODULATORS AND THEIR METHOD OF USE TEMPLE UNIVERSITY OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION 2020-10-08 US disclosed
US-20200317648-A1 NOVEL 5-HYDROXYTRYPTAMINE RECEPTOR 7 ACTIVITY MODULATORS AND THEIR METHOD OF USE TEMPLE UNIVERSITY OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION 2020-10-08 US disclosed
US-10676464-B2 5-hydroxytryptamine receptor 7 activity modulators and their method of use TEMPLE UNIVERSITY OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) 2020-06-09 US disclosed
WO-2014164756-A1 NOVEL 5-HYDROXYTRYPTAMINE RECEPTOR 7 ACTIVITY MODULATORS AND THEIR METHOD OF USE TEMPLE UNIVERSITY OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) 2014-10-09 WO disclosed
CN-1152015-C Piperazine devivatives and process for preparation thereof ������ҩ��ʽ���� 2004-06-02 CN disclosed
EP-0850222-B1 PIPERAZINE DERIVATIVES AND PROCESS FOR THE PREPARATION THEREOF SAMJIN PHARM CO LTD (KR) 2003-05-28 EP disclosed
US-6028195-A AN ANTITUMOR AGENT WITH VERY LOW TOXICITIES SAMJIN PHARMACEUTICAL CO., LTD. (KR) 2000-02-22 US disclosed
CN-1196724-A Novel piperazine derivative and process for producing the same SAMJIN PHARM CO LTD (KR) 1998-10-21 CN disclosed
US-5780472-A ANTITUMOR AGENTS SAMJIN PHARMACEUTICAZL CO., LTD. (KR) 1998-07-14 US disclosed
EP-0850222-A1 PIPERAZINE DERIVATIVES AND PROCESS FOR THE PREPARATION THEREOF Samjin Pharmaceutical Co., Ltd. (KR) 1998-07-01 EP disclosed
WO-1998000402-A1 PIPERAZINE DERIVATIVES AND PROCESS FOR THE PREPARATION THEREOF SAMJIN PHARMACEUTICAL CO., LTD. (KR) 1998-01-08 WO disclosed
EP-0749425-A1 NEW PIPERAZINE DERIVATIVES AND METHODS FOR THE PREPARATION THEREOF AND COMPOSITIONS CONTAINING THE SAME SAMJIN PHARM. CO., LTD. (KR) 1996-12-27 EP disclosed
WO-1996021648-A1 NEW PIPERAZINE DERIVATIVES AND METHODS FOR THE PREPARATION THEREOF AND COMPOSITIONS CONTAINING THE SAME SAMJIN PHARMACEUTICAL CO., LTD. (KR) 1996-07-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12503458-B2 5-hydroxytryptamine receptor 7 activity modulators and their method of use HTR7, HTR5A, HTR6 HTR6 3/4885HTR5A 2/4885HTR3E 15/4885
US-20200317648-A1 NOVEL 5-HYDROXYTRYPTAMINE RECEPTOR 7 ACTIVITY MODULATORS AND THEIR METHOD OF USE HTR7, HTR6, HTR5A HTR6 2/4885HTR5A 3/4885HTR3E 15/4885
US-10676464-B2 5-hydroxytryptamine receptor 7 activity modulators and their method of use HTR7, HTR5A, HTR6 HTR6 3/4885HTR5A 2/4885HTR3E 15/4885
US-20220133713-A1 SIGMA-2 RECEPTOR BINDERS AND THEIR METHOD OF USE SIGMAR1, TMEM97, OPRL1 HTR6 77/4885HTR5A 132/4885HTR3E 156/4885
US-11897870-B2 5-hydroxytryptamine receptor 7 activity modulators and their method of use HTR7, HTR5A, HTR6 HTR6 3/4885HTR5A 2/4885HTR3E 15/4885
US-20240425487-A1 NOVEL 5-HYDROXYTRYPTAMINE RECEPTOR 7 ACTIVITY MODULATORS AND THEIR METHOD OF USE HTR7, HTR6, HTR5A HTR6 2/4885HTR5A 3/4885HTR3E 15/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.